Biolife solutions reports second quarter 2024 financial results

Cell processing revenue increased 11%  sequentially to $18.0 million gaap gross margin of 51%  and non-gaap adjusted gross margin of 52% gaap net loss from continuing operations of $7.1 million and non-gaap adjusted ebitda of $4.8 million or 17% raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; cell processing revenue guidance increased to $70.0 million to $71.0 million conference call begins at 4:30 p.m. eastern time today bothell, wash.
BLFS Ratings Summary
BLFS Quant Ranking